IRLAB Therapeutics is a biotechnology company focused on Parkinson's disease (PD). It develops mesdopetam (IRL790) and IRL752 drug candidates to treat such symptoms related to PD as involuntary movements occurring upon long-term use of levodopa and impaired balance leading to falls. The company is also engaged in a range of research projects dedicated to diseases associated with the CNS (IRL942, IRL1009, P001, and P003).